% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Almouhanna:287409,
      author       = {F. Almouhanna and J. Hess$^*$},
      title        = {{A}n {ESR}1-{R}elated {G}ene {S}ignature {I}dentifies
                      {H}ead and {N}eck {S}quamous {C}ell {C}arcinoma with
                      {I}mputed {S}usceptibility to {E}ndocrine {T}herapy.},
      journal      = {International journal of molecular sciences},
      volume       = {25},
      number       = {2},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2024-00224},
      pages        = {1244},
      year         = {2024},
      note         = {#LA:E221#},
      abstract     = {Head and neck squamous cell carcinoma (HNSCC) is associated
                      with high morbidity and mortality. New personalized
                      treatment strategies represent an unmet medical need to
                      improve the overall survival and the quality of life of
                      patients, which are often limited by the toxicity of
                      established multimodal treatment protocols. Several studies
                      have reported an increased expression of the estrogen
                      receptor 1 (ESR1) in HNSCC, but its potential role in the
                      disease outcome of these tumors remains elusive. Using an
                      integrative analysis of multiomics and clinical data from
                      The Cancer Genome Atlas (TCGA)-HNSC, we established a
                      prognostic risk model based on an ESR1-related 25-gene set.
                      The prognostic value was confirmed in an independent cohort
                      of HNSCC and other solid tumors from TCGA. Finally, we
                      performed in silico drug sensitivity modeling to explore
                      potential vulnerabilities for both risk groups. This
                      approach predicted a higher sensitivity for HNSCC, with
                      prominent ESR1 pathway activity under treatment with
                      specific estrogen receptor modulators. In conclusion, our
                      data confirm the involvement of ESR1-related pathway
                      activity in the progression of a defined subset of HNSCC,
                      provide compelling evidence that these tumors share a
                      specific vulnerability to endocrine therapy, and pave the
                      way for preclinical studies and clinical trials to
                      demonstrate the efficacy of this new therapeutic option.},
      keywords     = {endocrine therapy (Other) / estrogen receptor alpha (Other)
                      / head and neck cancers (Other) / risk model (Other)},
      cin          = {E221},
      ddc          = {540},
      cid          = {I:(DE-He78)E221-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38279245},
      pmc          = {pmc:PMC10816965},
      doi          = {10.3390/ijms25021244},
      url          = {https://inrepo02.dkfz.de/record/287409},
}